Log in to MyACC
Cardiovascular (CV) disease is the leading cause of mortality in the US and globally contributing to more than 17 million deaths worldwide. For years, lowering LDL-cholesterol has been one of the primary targets for reducing CV risk, with statins as the established treatment. Recently, new science has emerged and is changing the landscape of how cardiologists and the broader CV team reduce CV risk in their patients. The goal of this page is to provide a resource to highlight the most relevant content on the emerging science in CV risk beyond LDL. Curated content will include new cutting-edge science along with foundational policy, education, and tools.
Guidelines and Policy
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- 2018 ACC/AHA Guideline on the Management of Blood Cholesterol
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Journal Scans
- Triglyceride Levels and Increased Medical Care Utilization
- Fasting Triglycerides and Prognosis After Acute Coronary Syndrome
- Triglycerides and Cardiovascular Disease
- Loss-of-Function Mutations in APOC3, Triglycerides and Coronary Disease
- Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study
- Association Between Plasma Triglycerides and HDL-Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes: A Global Case-Control Study in 13 Countries
- Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management
- Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
- Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE Study
Clinical Tools and Patient Resources:
Expert Analysis:
- No One Hit Wonder: High-Dose EPA Reduces Total Ischemic Events
- Triglycerides, Remnant Cholesterol and Atherosclerotic Cardiovascular Disease
- Hypertriglyceridemia Management According to the 2018 AHA/ACC Guideline
- EPA Rises From a Dead Sea of Omega-3: The Landmark REDUCE-IT Trial
- Not All Fish Oils Are Created Equal: Insight From REDUCE-IT
- New Aspects of the Risk Assessment Guidelines: Practical Highlights, Scientific Evidence and Future Goals
- Managing Dyslipidemia in Primary Prevention
- Optimizing Non-Fasting Lipid Analysis in the Era of Precision Medicine
- How Low Should We Decrease LDL-Cholesterol in a Cost-Effective Manner?
- Patients With Very High Triglycerides and Treatment With Omega-3s
Patient Cases:
- Blurred Lines: The High-Risk Patient With Subclinical Atherosclerosis
- Hypertriglyceridemia-Induced Pancreatitis During Pregnancy
Other Articles:
- REDUCE-IT: Does Icosapent Ethyl Represent New Pathway For Reducing CV Risk?
- Is There Potential Clinical Benefit of Lowering Triglycerides Through LPL Pathway?
- Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease
- Hypertriglyceridemia: Insights on Needs of Cardiologists, CV Team to Reduce Residual Risk
- Remnants of Residual Risk: Triglycerides Predict Recurrent Events
- Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
Images and Slides:
- Primary Prevention Guideline Slides
- REDUCE-IT Total Events Presentation Slides
- REDUCE-IT Summary Slide
- REDUCE-IT Visual Abstract
- REDUCE-IT Presentation Slides
- Blood Cholesterol Guideline Slides
